On this basis, the expression of FAK, when PYK2 or LYN expression is absent or low, may confer a highly aggressive phenotype to IR-AML patients, likely also in patients with non-favorable FLT3/NMP1, because their leukemia may contain a higher proportion of progenitor/LSCs, and show higher dissemination and drug resistance capacities. This evidence concerns the gene PTK2B and acute myeloid leukemia.